214
Merck and its partner Ridgeback Biotherapeutics announced that their Covid experimental pill reduced the risk of death and hospitalization in at-risk patients by 30%. This was a lower efficacy rate than that seen in a previous study which indicated a reduction of nearly 50%. On Wall Street, Merck shares lost 3.5%.